Previously doing business as Ultrathin Film Technology and briefly as Novatarg, Novatarg Pharmaceuticals, a bio/pharmaceutical drug discovery and diagnostic startup. Core business is developing specialized membrane protein targeted products to address significant unmet needs in a wide range of serious and debilitating diseases including cancer, cardiac disorders, diabetes, allergy, inflammation, Alzheimerâs Diseases and other central nervous system disorders. Novatarg has pioneered an novel approach to accelerate development of molecularly targeted therapies and companion molecular diagnostic devices against membrane proteins. Novatarg leverages its unique enabling nanotechnology platform - specifically designed to characterize three-dimensional structures of membrane proteins - together with its unparalleled capabilities for membrane protein molecular imaging and screening, to develop more effective targeted drugs faster and at significantly reduced costs. This integrated approach has potential to lead to major advances in developing novel targeted drugs, drug leads and research tools for G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs) and other membrane proteins involved in disease. Specifically Novatargâs advances facilitate design and development of selective allosteric inhibitors as new pharmacological modalities that overcome resistance associated with conventional active-site inhibitors. These advances have utility for multiple human disorders, including cancer, diseases of the central nervous system (CNS) and neurodegenerative disorders such as Alzheimerâs Disease, and to overcome multidrug resist
